Nomenclature: CCK2 receptor

Family: Cholecystokinin receptors

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates. 

Contents

Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 447 11p15.4 CCKBR cholecystokinin B receptor 24,32,39,53
Mouse 7 453 7 E3 Cckbr cholecystokinin B receptor 58
Rat 7 452 1q33 Cckbr cholecystokinin B receptor 59
Previous and Unofficial Names
CCK-B
CCK-B/gastrin
CCKB/gastrin
CCKB
CHOLREC
Cck2r
CCK(B) receptor
CCK-B receptor
CCK-BR
CCK2 receptor
CCK2-R
Cholecystokinin B receptor
cholecystokinin-2 receptor
gastrin/cholecystokinin type B receptor
CCK-B/gastrin receptor
CCK2/gastrin
CCKR-2
Database Links
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
GPCRDB
GeneCards
GenitoUrinary Development Molecular Anatomy Project
HomoloGene
Human Protein Reference Database
InterPro
KEGG Gene
OMIM
PharmGKB Gene
PhosphoSitePlus
Protein Ontology (PRO)
RefSeq Nucleotide
RefSeq Protein
TreeFam
UniGene Hs.
UniProtKB
Wikipedia
Natural/Endogenous Ligand(s)
CCK-33 {Sp: Rat} , CCK-33 {Sp: Human} , CCK-33 {Sp: Mouse}
CCK-4 {Sp: Human}
CCK-8 {Sp: Human, Mouse, Rat}
gastrin-17 {Sp: Human} , gastrin-17 {Sp: Mouse} , gastrin-17 {Sp: Rat}
Rank order of potency (Human)
CCK-8 (CCK, P06307) ≥ gastrin-17 (GAST, P01350), CCK-8 (desulphated), CCK-4 (CCK, P06307)
Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
RB-400 Rn Full agonist 9.1 pKi 5
pKi 9.1 [5]
BBL-454 Rn Full agonist 8.6 pKi 5
pKi 8.6 [5]
BC-254 Rn Full agonist 7.4 pKi 18
pKi 7.4 [18]
ARL-15849 Rn Full agonist 6.6 pKi 50
pKi 6.6 [50]
CCK-8 {Sp: Human, Mouse, Rat} Hs Full agonist 9.9 – 10.0 pIC50 24,32
pIC50 9.9 – 10.0 [24,32]
BC-264 Rn Full agonist 9.5 pIC50 5
pIC50 9.5 [5]
CCK-58 {Sp: Dog} Mm Full agonist 9.5 pIC50 42
pIC50 9.5 [42]
pentagastrin Mm Full agonist 9.1 pIC50 22
pIC50 9.1 [22]
PBC-264 Rn Full agonist 9.1 pIC50 25
pIC50 9.1 (IC50 8.6x10-10 M) [25]
[125I]DTyr-Gly-[(Nle28,31)CCK-26-33 Hs Full agonist 9.0 pIC50 40
pIC50 9.0 (IC50 1x10-9 M) [40]
CCK-33 {Sp: Human} Hs Full agonist 8.8 pIC50 24
pIC50 8.8 [24]
CCK-8 (desulphated) Hs Full agonist 8.3 – 8.7 pIC50 32
pIC50 8.3 – 8.7 [32]
JMV310 Rn Full agonist 8.4 pIC50 45
pIC50 8.4 [45]
gastrin-17 {Sp: Human} Mm Full agonist 8.3 pIC50 22
pIC50 8.3 [22]
CCK-4 {Sp: Human} Hs Full agonist 7.5 pIC50 24
pIC50 7.5 [24]
A-71378 Hs Full agonist 6.5 pIC50 17
pIC50 6.5 [17]
View species-specific agonist tables
Agonist Comments
pIC50 values represent inhibition of binding of [125I]CCK.
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[3H]JB-93182 Rn Antagonist 9.5 pKd 19
pKd 9.5 [19]
[3H]L365260 Hs Antagonist 8.2 – 8.5 pKd 38
pKd 8.2 – 8.5 (Kd 2.9x10-9 – 5.7x10-9 M) [38]
[3H]PD140376 Cp Antagonist 9.7 – 10.0 pKi 23
pKi 9.7 – 10.0 (Ki 1x10-10 – 2x10-10 M) [23]
YF-476 Hs Antagonist 9.6 pKi 38
pKi 9.6 [38]
Z-360 Hs Antagonist 9.3 pKi 27
pKi 9.3 [27]
[125I]-BDZ2 Hs Antagonist 8.4 pKi 1
pKi 8.4 (Ki 3.98x10-9 M) [1]
AG-041R Hs Antagonist 8.3 pKi 38
pKi 8.3 [38]
RP-69758 Rn Antagonist 8.0 pKi 6
pKi 8.0 [6]
TP-680 Rn Antagonist 5.7 pKi 2
pKi 5.7 [2]
PD-149164 Mm Antagonist 10.1 pIC50 4
pIC50 10.1 [4]
PD-135666 Mm Antagonist 9.8 pIC50 51
pIC50 9.8 [51]
YF-476 Hs Antagonist 9.7 pIC50 9,54
pIC50 9.7 [9,54]
GV150013 Hs Antagonist 9.4 pIC50 57
pIC50 9.4 [57]
L-740093 Hs Antagonist 9.2 pIC50 38
pIC50 9.2 [38]
YM-022 Hs Antagonist 9.2 pIC50 38
pIC50 9.2 [38]
CI-988 Hs Antagonist 9.1 pIC50 17
pIC50 9.1 [17]
PD-135158 Hs Antagonist 8.9 pIC50 17
pIC50 8.9 [17]
CI-988 Mm Antagonist 8.8 pIC50 22
pIC50 8.8 [22]
itriglumide Rn Antagonist 8.6 pIC50 34
pIC50 8.6 [34]
JNJ-26070109 Hs Antagonist 8.5 pIC50 36
pIC50 8.5 [36]
CI-1015 Mm Antagonist 8.5 pIC50 56
pIC50 8.5 [56]
L-365260 Hs Antagonist 8.4 pIC50 32
pIC50 8.4 [32]
RP73870 Rn Antagonist 8.0 pIC50 33
pIC50 8.0 (IC50 9.8x10-9 M) [33]
LY262691 Rn Antagonist 7.5 pIC50 41
pIC50 7.5 (IC50 3.1x10-8 M) [41]
LY-288513 Hs Antagonist 7.0 pIC50 17
pIC50 7.0 [17]
devazepide Hs Antagonist 6.8 pIC50 32
pIC50 6.8 [32]
tetronothiodin Hs Antagonist 6.7 pIC50 29
pIC50 6.7 [29]
PD-140548 Rn Antagonist 6.6 pIC50 8
pIC50 6.6 [8]
GW-5823 Hs Antagonist 6.0 pIC50 21
pIC50 6.0 [21]
lorglumide Hs Antagonist 5.5 pIC50 17
pIC50 5.5 [17]
View species-specific antagonist tables
Primary Transduction Mechanisms
Transducer Effector/Response
Gq/G11 family Phospholipase C stimulation
References:  32
Tissue Distribution
Stomach.
Species:  Human
Technique:  RT-PCR, autoradiography, immunohistochemistry.
References:  28,44,47
Exocrine pancreas.
Species:  Human
Technique:  RT-PCR, Northern blot, radioligand binding.
References:  13,26,39,55
Endocrine pancreas.
Species:  Human
Technique:  In situ hybridization, receptor autoradiography, immunohistochemistry.
References:  43,46
Adrenal gland.
Species:  Human
Technique:  RT-PCR.
References:  35
Blood cells.
Species:  Human
Technique:  RT-PCR.
References:  14,48
Adipocytes.
Species:  Rat
Technique:  RT-PCR, radioligand binding.
References:  3
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
COS cells transiently transfected with human CCK2 receptor cDNA.
Species:  Human
Tissue:  COS cells.
Response measured:  IP3 production.
References:  32
CHO cells stably transfected with human CCK2 receptor cDNA.
Species:  Human
Tissue:  CHO cells.
Response measured:  Intracellular Ca2+ (Fura-2 AM).
References:  24
COS cells transiently transfected with human CCK2 receptor cDNA.
Species:  Human
Tissue:  COS cells.
Response measured:  Intracellular Ca2+ (Fura-2 AM).
References:  32
CHO cells stably transfected with human CCK2 receptor cDNA.
Species:  Human
Tissue:  CHO cells.
Response measured:  IP3 production.
References:  24
Physiological Functions
The transfer of rats from a familiar to a novel environment prolongs the increase of extracellular dopamine efflux induced by CCK-8 in the posterior nucleus accumbens.
Species:  Rat
Tissue:  Nucleus accumbens.
References:  30
Rat hippocampal neurones are critically involved in physiological improvement of memory processes induced by CCK2 receptor stimulation.
Species:  Rat
Tissue:  Hippocampal neurones.
References:  49
CCK in the perfusion medium produced a concentration-dependent increase in firing rate of neurones located in ventromedial nuclei of rat hypothalamic slices.
Species:  Rat
Tissue:  Ventromedial nuclei of rat hypothalamus.
References:  7
CCK2 receptor agonists affect nociception and behaviour in rodents.
Species:  Mouse
Tissue:  In vivo (brain).
References:  15
CCK2 receptor antagonist produced an anxiolytic-like action in rats.
Species:  Rat
Tissue:  In vivo (brain).
References:  56
Physiological Consequences of Altering Gene Expression
CCK2 receptor-deficient mice showed an impairment of performance in spontaneous alternation behaviour, supporting the physiological role of CCK2 receptors in attention and/or memory processes.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  16
CCK2 receptor-deficient mice showed a remarkable atrophy of the gastric mucosa.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  37
CCK2 receptor-deficient mice showed a marked increase in basal gastric pH and in plasma gastrin concentration. In the stomach of mutant mice, parietal and enterochromaffin-like cells were decreased. In the antrum, somatostatin cell density decreases and the gastrin cell number increases.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  31
CCK2 receptor-deficient mice showed altered differentiation of gastric ECL cells.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  11
CCK2 receptor-deficient mice showed hyperphagia and increased fat deposition.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  12
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
B6.129S4-Cckbr
MGI:99479  MP:0004924 abnormal behavior PMID: 15325774 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6J
MGI:99479  MP:0004924 abnormal behavior PMID: 11682252 
Cckartm1Kym|Cckbrtm1Tom Cckartm1Kym/Cckartm1Kym,Cckbrtm1Tom/Cckbrtm1Tom
B6.129S4-Cckar Cckbr
MGI:99478  MGI:99479  MP:0004924 abnormal behavior PMID: 12459512 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
B6.129S4-Cckbr
MGI:99479  MP:0002128 abnormal blood circulation PMID: 15355324 
Cckartm1Kym|Cckbrtm1Tom Cckartm1Kym/Cckartm1Kym,Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6J
MGI:99478  MGI:99479  MP:0001777 abnormal body temperature regulation PMID: 15178543 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6J
MGI:99479  MP:0004152 abnormal circulating iron level PMID: 18755804 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6J
MGI:99479  MP:0001663 abnormal digestive system physiology PMID: 8876222 
Cckbrtm1Kpn Cckbrtm1Kpn/Cckbrtm1Kpn
involves: 129S2/SvPas
MGI:99479  MP:0004141 abnormal enteroendocrine cell morphology PMID: 8978369 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6J
MGI:99479  MP:0002910 abnormal excitatory postsynaptic currents PMID: 20392936 
Cckbrtm1Kpn Cckbrtm1Kpn/Cckbrtm1Kpn
involves: 129S2/SvPas
MGI:99479  MP:0003892 abnormal gastric gland PMID: 8978369 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6J
MGI:99479  MP:0005209 abnormal gastric mucosa morphology PMID: 8876222 
Cckbrtm1Kpn Cckbrtm1Kpn/Cckbrtm1Kpn
involves: 129S2/SvPas
MGI:99479  MP:0004139 abnormal gastric parietal cell morphology PMID: 8978369 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
B6.129S4-Cckbr
MGI:99479  MP:0002736 abnormal nociception after inflammation PMID: 15355324 
Cckbrtm1Kpn Cckbrtm1Kpn/Cckbrtm1Kpn
involves: 129S2/SvPas
MGI:99479  MP:0005218 abnormal pancreatic delta cell morphology PMID: 8978369 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6
MGI:99479  MP:0008872 abnormal physiological response to xenobiotic PMID: 11403953 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6J
MGI:99479  MP:0000470 abnormal stomach morphology PMID: 8876222 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
B6.129S4-Cckbr
MGI:99479  MP:0001364 decreased anxiety-related response PMID: 15325774 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6J
MGI:99479  MP:0001364 decreased anxiety-related response PMID: 15013032 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
B6.129S4-Cckbr
MGI:99479  MP:0001262 decreased body weight PMID: 15325774 
Cckartm1Kym|Cckbrtm1Tom Cckartm1Kym/Cckartm1Kym,Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6J
MGI:99478  MGI:99479  MP:0001262 decreased body weight PMID: 15178543 
Cckartm1Kym|Cckbrtm1Tom Cckartm1Kym/Cckartm1Kym,Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae
MGI:99478  MGI:99479  MP:0001262 decreased body weight PMID: 11925470  15168241 
Cckartm1Kym|Cckbrtm1Tom Cckartm1Kym/Cckartm1Kym,Cckbrtm1Tom/Cckbrtm1Tom
B6.129S4-Cckar Cckbr
MGI:99478  MGI:99479  MP:0001262 decreased body weight PMID: 12459512 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
B6.129S4-Cckbr
MGI:99479  MP:0001442 decreased grooming behavior PMID: 15325774 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6J
MGI:99479  MP:0008734 decreased susceptibility to endotoxin shock PMID: 16857893 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae
MGI:99479  MP:0009854 delayed gastric emptying PMID: 15168241 
Cckartm1Kym|Cckbrtm1Tom Cckartm1Kym/Cckartm1Kym,Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae
MGI:99478  MGI:99479  MP:0009854 delayed gastric emptying PMID: 15168241 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6
MGI:99479  MP:0009749 enhanced behavioral response to addictive substance PMID: 11403953 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6
MGI:99479  MP:0009753 enhanced behavioral response to morphine PMID: 11403953 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6J
MGI:99479  MP:0001399 hyperactivity PMID: 11682252  16857893 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6
MGI:99479  MP:0001399 hyperactivity PMID: 11403953 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
B6.129S4-Cckbr
MGI:99479  MP:0005498 hyporesponsive to tactile stimuli PMID: 15355324 
Cckbr+|Cckbrtm1Tom Cckbrtm1Tom/Cckbr+
B6.129S4-Cckbr
MGI:99479  MP:0005498 hyporesponsive to tactile stimuli PMID: 15355324 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6
MGI:99479  MP:0009758 impaired behavioral response to cocaine PMID: 11403953 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6J
MGI:99479  MP:0001405 impaired coordination PMID: 11682252 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6J
MGI:99479  MP:0003829 impaired febrile response PMID: 16857893 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
B6.129S4-Cckbr
MGI:99479  MP:0001363 increased anxiety-related response PMID: 12459512 
Cckbrtm1Kpn Cckbrtm1Kpn/Cckbrtm1Kpn
involves: 129S2/SvPas
MGI:99479  MP:0004731 increased circulating gastrin level PMID: 8978369 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6J
MGI:99479  MP:0004731 increased circulating gastrin level PMID: 18755804  8876222 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae
MGI:99479  MP:0004731 increased circulating gastrin level PMID: 15168241 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6J
MGI:99479  MP:0003911 increased drinking behavior PMID: 16857893 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6J
MGI:99479  MP:0003909 increased eating behavior PMID: 16857893 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae
MGI:99479  MP:0003909 increased eating behavior PMID: 11925470 
Cckartm1Kym|Cckbrtm1Tom Cckartm1Kym/Cckartm1Kym,Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae
MGI:99478  MGI:99479  MP:0003909 increased eating behavior PMID: 11925470 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae
MGI:99479  MP:0004889 increased energy expenditure PMID: 11925470 
Cckartm1Kym|Cckbrtm1Tom Cckartm1Kym/Cckartm1Kym,Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae
MGI:99478  MGI:99479  MP:0004889 increased energy expenditure PMID: 11925470 
Cckartm1Kym|Cckbrtm1Tom Cckartm1Kym/Cckartm1Kym,Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae
MGI:99478  MGI:99479  MP:0003917 increased kidney weight PMID: 11925470 
Cckbrtm1Tom Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae * C57BL/6J
MGI:99479  MP:0008807 increased liver iron level PMID: 18755804 
Cckartm1Kym|Cckbrtm1Tom Cckartm1Kym/Cckartm1Kym,Cckbrtm1Tom/Cckbrtm1Tom
involves: 129S4/SvJae
MGI:99478  MGI:99479  MP:0009108 increased pancreas weight PMID: 11925470 
Cckbrtm1Kpn Cckbrtm1Kpn/Cckbrtm1Kpn
involves: 129S2/SvPas
MGI:99479  MP:0008006 increased stomach pH PMID: 8978369 
Biologically Significant Variants
Type:  Splice variant.
Species:  Human
Description:  A splice variant of the CCK2 receptor was identified which differed from the predominant CCK2 receptor isoform by the presence of intron 4. This variant was identified in human pancreatic cancer specimens and plays a crucial role in the growth of pancreatic cancer.
References:  52
Type:  Splice variant.
Species:  Human
Description:  A splice variant of the CCK2 receptor was identified with additional amino acids (GGAGP) in exon 4 by screening a human EMBL phage library.
References:  53
Type:  Splice variant.
Species:  Human
Description:  A splice variant of the CCK2 receptor identified in intron 4 is expressed in colorectal cancers but not in the normal colonic mucosa adjacent to the cancer. This variant receptor is constitutively active in tumour cells, and increases Src-dependent HIF-1α expression and tumour growth.
References:  10,20
Available Assays
DiscoveRx PathHunter® CHO-K1 CCKBR β-Arrestin Cell Line (Cat no. 93-0191C2)
PathHunter® eXpress CCKBR CHO-K1 β-Arrestin GPCR Assay (Cat no. 93-0191E2CP0M)
more info

REFERENCES

1. Akgün E, Körner M, Gao F, Harikumar KG, Waser B, Reubi JC, Portoghese PS, Miller LJ. (2009) Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors. J. Med. Chem.52 (7): 2138-47. [PMID:19271701]

2. Akiyama T, Tachibana I, Hirohata Y, Shirohara H, Yamamoto M, Otsuki M. (1996) Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist. Br J Pharmacol117: 1558-1564. [PMID:8730754]

3. Attoub S, Levasseur S, Buyse M, Goïot H, Laigneau JP, Moizo L, Hervatin F, Le Marchand-Brustel Y, Lewin JM, Bado A. (1999) Physiological role of cholecystokinin B/gastrin receptor in leptin secretion. Endocrinology140: 4406-4410. [PMID:10499492]

4. Augelli-Szafran CE, Horwell DC, Kneen C, Ortwine DF, Pritchard MC, Purchase TS, Roth BD, Trivedi BK, Hill D, Suman-Chauhan N, Webdale L. (1996) Cholecystokinin B antagonists. Synthesis and quantitative structure-activity relationships of a series of C-terminal analogues of CI-988. Bioorg Med Chem4: 1733-1745. [PMID:8931944]

5. Bellier B, Dugave C, Etivant F, Genet R, Gigoux V, Garbay C. (2004) Synthesis and biological characterisation of [3H]BBL454, a new CCK2 selective radiolabelled agonist displaying original pharmacological properties. Bioorg Med Chem Lett14: 369-372. [PMID:14698161]

6. Bertrand P, Böhme GA, Durieux C, Guyon C, Capet M, Jeantaud B, Boudeau P, Ducos B, Pendley CE, Martin GE. (1994) Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists. Eur J Pharmacol262: 233-245. [PMID:7813588]

7. Boden P, Hill RG. (1988) Effects of cholecystokinin and related peptides on neuronal activity in the ventromedial nucleus of the rat hypothalamus. Br J Pharmacol94: 246-252. [PMID:3401640]

8. Boden PR, Higginbottom M, Hill DR, Horwell DC, Hughes J, Rees DC, Roberts E, Singh L, Suman-Chauhan N, Woodruff GN. (1993) Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists. J Med Chem36: 552-565. [PMID:7684452]

9. Boyce M, David O, Darwin K, Mitchell T, Johnston A, Warrington S. (2012) Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. Aliment. Pharmacol. Ther.36 (2): 181-9. [PMID:22607579]

10. Chao C, Goluszko E, Lee YT, Kolokoltsov AA, Davey RA, Uchida T, Townsend CM, Hellmich MR. (2007) Constitutively active CCK2 receptor splice variant increases Src-dependent HIF-1 alpha expression and tumor growth. Oncogene26: 1013-1019. [PMID:16909104]

11. Chen D, Zhao CM, Al-Haider W, Håkanson R, Rehfeld JF, Kopin AS. (2002) Differentiation of gastric ECL cells is altered in CCK(2) receptor-deficient mice. Gastroenterology123: 577-585. [PMID:12145810]

12. Clerc P, Coll Constans MG, Lulka H, Broussaud S, Guigné C, Leung-Theung-Long S, Perrin C, Knauf C, Carpéné C, Pénicaud L, Seva C, Burcelin R, Valet P, Fourmy D, Dufresne M. (2007) Involvement of cholecystokinin 2 receptor in food intake regulation: hyperphagia and increased fat deposition in cholecystokinin 2 receptor-deficient mice. Endocrinology148: 1039-1049. [PMID:17122076]

13. Clerc P, Dufresne M, Saillan C, Chastre E, André T, Escrieut C, Kennedy K, Vaysse N, Gespach C, Fourmy D. (1997) Differential expression of the CCK-A and CCK-B/gastrin receptor genes in human cancers of the esophagus, stomach and colon. Int J Cancer72: 931-936. [PMID:9378553]

14. Cuq P, Gross A, Terraza A, Fourmy D, Clerc P, Dornand J, Magous R. (1997) mRNAs encoding CCKB but not CCKA receptors are expressed in human T lymphocytes and Jurkat lymphoblastoid cells. Life Sci61: 543-555. [PMID:9247324]

15. Daugé V, Derrien M, Durieux C, Noble F, Corringer PJ, Roques BP. (1992) [Study of induced effects by selective CCKB agonists cholecystokinin in the nociception and behavior in rodents]. Therapie47: 531-539. [PMID:1301645]

16. Daugé V, Sebret A, Beslot F, Matsui T, Roques BP. (2001) Behavioral profile of CCK2 receptor-deficient mice. Neuropsychopharmacology25: 690-698. [PMID:11682252]

17. Dunlop J, Brammer N, Ennis C. (1996) Pharmacological characterization of a Chinese hamster ovary cell line transfected with the human CCK-B receptor gene. Neuropeptides30: 359-363. [PMID:8914862]

18. Durieux C, Ruiz-Gayo M, Corringer PJ, Bergeron F, Ducos B, Roques BP. (1992) [3H]pBC 264, a suitable probe for studying cholecystokinin-B receptors: binding characteristics in rodent brains and comparison with [3H]SNF 8702. Mol Pharmacol41: 1089-1095. [PMID:1614411]

19. Harper EA, Shankley NP, Black JW. (1999) Characterization of the binding of a novel radioligand to CCKB/gastrin receptors in membranes from rat cerebral cortex. Br J Pharmacol126: 1504-1512. [PMID:10217546]

20. Hellmich MR, Rui XL, Hellmich HL, Fleming RY, Evers BM, Townsend CM. (2000) Human colorectal cancers express a constitutively active cholecystokinin-B/gastrin receptor that stimulates cell growth. J Biol Chem275: 32122-32128. [PMID:10913157]

21. Henke BR, Aquino CJ, Birkemo LS, Croom DK, Dougherty RW, Ervin GN, Grizzle MK, Hirst GC, James MK, Johnson MF, Queen KL, Sherrill RG, Sugg EE, Suh EM, Szewczyk JW, Unwalla RJ, Yingling J, Willson TM. (1997) Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists. J Med Chem40: 2706-2725. [PMID:9276016]

22. Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter JC, Pinnock RD, Woodruff GN. (1990) Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci U S A87: 6728-6732. [PMID:1975695]

23. Hunter JC, Suman-Chauhan N, Meecham KG, Dissanayake VU, Hill DR, Pritchard MC, Kneen CO, Horwell DC, Hughes J, Woodruff GN. (1993) [3H]PD 140376: a novel and highly selective antagonist radioligand for the cholecystokininB/gastrin receptor in guinea pig cerebral cortex and gastric mucosa. Mol. Pharmacol.43 (4): 595-602. [PMID:8474432]

24. Ito M, Matsui T, Taniguchi T, Tsukamoto T, Murayama T, Arima N, Nakata H, Chiba T, Chihara K. (1993) Functional characterization of a human brain cholecystokinin-B receptor. A trophic effect of cholecystokinin and gastrin. J Biol Chem268: 18300-18305. [PMID:8349705]

25. Jagerschmidt A, Guillaume-Rousselet N, Vikland ML, Goudreau N, Maigret B, Roques BP. (1996) His381 of the rat CCKB receptor is essential for CCKB versus CCKA receptor antagonist selectivity. Eur. J. Pharmacol.296 (1): 97-106. [PMID:8720482]

26. Ji B, Bi Y, Simeone D, Mortensen RM, Logsdon CD. (2001) Human pancreatic acinar cells lack functional responses to cholecystokinin and gastrin. Gastroenterology121: 1380-1390. [PMID:11729117]

27. Kawasaki D, Emori Y, Eta R, Iino Y, Hamano H, Yoshinaga K, Tanaka T, Takei M, Watson SA. (2007) Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro. Cancer Chemother Pharmacol, : -. [PMID:17901954]

28. Kulaksiz H, Arnold R, Göke B, Maronde E, Meyer M, Fahrenholz F, Forssmann WG, Eissele R. (2000) Expression and cell-specific localization of the cholecystokinin B/gastrin receptor in the human stomach. Cell Tissue Res299: 289-298. [PMID:10741470]

29. Kuwahara T, Kudoh T, Nakano A, Yoshizaki H, Takamiya M, Nagase H, Arisawa M. (1993) Species specificity of pharmacological characteristics of CCK-B receptors. Neurosci Lett158: 1-4. [PMID:8233061]

30. Ladurelle N, Roques BP, Daugé V. (1995) The transfer of rats from a familiar to a novel environment prolongs the increase of extracellular dopamine efflux induced by CCK8 in the posterior nucleus accumbens. J Neurosci15: 3118-3127. [PMID:7722650]

31. Langhans N, Rindi G, Chiu M, Rehfeld JF, Ardman B, Beinborn M, Kopin AS. (1997) Abnormal gastric histology and decreased acid production in cholecystokinin-B/gastrin receptor-deficient mice. Gastroenterology112: 280-286. [PMID:8978369]

32. Lee YM, Beinborn M, McBride EW, Lu M, Kolakowski LF, Kopin AS. (1993) The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. J Biol Chem268: 8164-8169. [PMID:7681836]

33. Lindström E, Björkqvist M, Håkanson R. (1999) Pharmacological analysis of CCK2 receptor antagonists using isolated rat stomach ECL cells. Br. J. Pharmacol.127 (2): 530-6. [PMID:10385255]

34. Makovec F, Revel L, Letari O, Mennuni L, Impicciatore M. (1999) Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK(B) receptor antagonist. Eur J Pharmacol369: 81-90. [PMID:10204685]

35. Mazzocchi G, Malendowicz LK, Aragona F, Spinazzi R, Nussdorfer GG. (2004) Cholecystokinin (CCK) stimulates aldosterone secretion from human adrenocortical cells via CCK2 receptors coupled to the adenylate cyclase/protein kinase A signaling cascade. J Clin Endocrinol Metab89: 1277-1284. [PMID:15001623]

36. Morton MF, Barrett TD, Freedman J, Li L, Rizzolio MC, Prendergast CE, Wu X, Moreno V, Pyati J, Figueroa K et al.. (2011) JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. J. Pharmacol. Exp. Ther.338 (1): 328-36. [PMID:21493750]

37. Nagata A, Ito M, Iwata N, Kuno J, Takano H, Minowa O, Chihara K, Matsui T, Noda T. (1996) G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo. Proc Natl Acad Sci U S A93: 11825-11830. [PMID:8876222]

38. Nilsson I, Monstein HJ, Lindström E, Håkanson R, Svensson S. (2002) Pharmacological analysis of CCK(2) receptor ligands using COS-7 and SK-N-MC cells, expressing the human CCK(2) receptor. Regul Pept103: 29-37. [PMID:11738246]

39. Pisegna JR, de Weerth A, Huppi K, Wank SA. (1992) Molecular cloning of the human brain and gastric cholecystokinin receptor: structure, functional expression and chromosomal localization. Biochem Biophys Res Commun189: 296-303. [PMID:1280419]

40. Powers SP, Pinon DI, Miller LJ. (1988) Use of N,O-bis-Fmoc-D-Tyr-ONSu for introduction of an oxidative iodination site into cholecystokinin family peptides. Int. J. Pept. Protein Res.31 (5): 429-34. [PMID:3410633]

41. Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, Devree BT, Rosenbaum DM, Thian FS, Kobilka TS et al.. (2011) Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. Nature469 (7329): 175-80. [PMID:21228869]

42. Reeve JR, McVey DC, Bunnett NW, Solomon TE, Keire DA, Ho FJ, Davis MT, Lee TD, Shively JE, Vigna SR. (2002) Differences in receptor binding and stability to enzymatic digestion between CCK-8 and CCK-58. Pancreas25: e50-e55. [PMID:12370550]

43. Reubi JC, Waser B, Gugger M, Friess H, Kleeff J, Kayed H, Büchler MW, Laissue JA. (2003) Distribution of CCK1 and CCK2 receptors in normal and diseased human pancreatic tissue. Gastroenterology125: 98-106. [PMID:12851875]

44. Reubi JC, Waser B, Läderach U, Stettler C, Friess H, Halter F, Schmassmann A. (1997) Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. Gastroenterology112: 1197-1205. [PMID:9098003]

45. Rodriguez M, Lignon MF, Galas MC, Amblard M, Martinez J. (1990) Cyclic cholecystokinin analogues that are highly selective for rat and guinea pig central cholecystokinin receptors. Mol Pharmacol38: 333-341. [PMID:1698251]

46. Saillan-Barreau C, Dufresne M, Clerc P, Sanchez D, Corominola H, Moriscot C, Guy-Crotte O, Escrieut C, Vaysse N, Gomis R, Tarasova N, Fourmy D. (1999) Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes48: 2015-2021. [PMID:10512367]

47. Schmitz F, Göke MN, Otte JM, Schrader H, Reimann B, Kruse ML, Siegel EG, Peters J, Herzig KH, Fölsch UR, Schmidt WE. (2001) Cellular expression of CCK-A and CCK-B/gastrin receptors in human gastric mucosa. Regulatory Peptides102: 101-110. [PMID:11730982]

48. Schmitz F, Schrader H, Otte JM, Schmitz H, Stuber E, Herzig KH, Schmidt WE. (2001) Identification of CCK-B/gastrin receptor splice variants in human peripheral blood mononuclear cells. Regulatory Peptides101: 25-33. [PMID:11495676]

49. Sebret A, Lena I, Crété D, Matsui T, Roques BP, Daugé V. (1999) Rat hippocampal neurons are critically involved in physiological improvement of memory processes induced by cholecystokinin-B receptor stimulation. J Neurosci19: 7230-7237. [PMID:10436075]

50. Simmons RD, Kaiser FC, Pierson ME, Rosamond JR. (1998) ARL 15849: a selective CCK-A agonist with anorectic activity in the rat and dog. Pharmacol Biochem Behav59: 439-444. [PMID:9476993]

51. Singh L, Field MJ, Hill DR, Horwell DC, McKnight AT, Roberts E, Tang KW, Woodruff GN. (1995) Peptoid CCK receptor antagonists: pharmacological evaluation of CCKA, CCKB and mixed CCKA/B receptor antagonists. Eur J Pharmacol286: 185-191. [PMID:8605955]

52. Smith JP, Verderame MF, McLaughlin P, Martenis M, Ballard E, Zagon IS. (2002) Characterization of the CCK-C (cancer) receptor in human pancreatic cancer. Int J Mol Med10: 689-694. [PMID:12429993]

53. Song I, Brown DR, Wiltshire RN, Gantz I, Trent JM, Yamada T. (1993) The human gastrin/cholecystokinin type B receptor gene: alternative splice donor site in exon 4 generates two variant mRNAs. Proc Natl Acad Sci U S A90: 9085-9089. [PMID:8415658]

54. Takinami Y, Yuki H, Nishida A, Akuzawa S, Uchida A, Takemoto Y, Ohta M, Satoh M, Semple G, Miyata K. (1997) YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo. Aliment. Pharmacol. Ther.11 (1): 113-20. [PMID:9042983]

55. Tang C, Biemond I, Lamers CB. (1996) Cholecystokinin receptors in human pancreas and gallbladder muscle: a comparative study. Gastroenterology111: 1621-1626. [PMID:8942742]

56. Trivedi BK, Padia JK, Holmes A, Rose S, Wright DS, Hinton JP, Pritchard MC, Eden JM, Kneen C, Webdale L, Suman-Chauhan N, Boden P, Singh L, Field MJ, Hill D. (1998) Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R) -tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. J Med Chem41: 38-45. [PMID:9438020]

57. Ursini A, Capelli AM, Carr RA, Cassarà P, Corsi M, Curcuruto O, Curotto G, Dal Cin M, Davalli S, Donati D et al.. (2000) Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists. J. Med. Chem.43 (20): 3596-613. [PMID:11020274]

58. Wank SA, Harkins R, Jensen RT, Shapira H, de Weerth A, Slattery T. (1992) Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas. Proc Natl Acad Sci U S A89: 3125-3129. [PMID:1313582]

59. Wank SA, Pisegna JR, de Weerth A. (1992) Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression. Proc Natl Acad Sci U S A89: 8691-8695. [PMID:1528881]

To cite this database page, please use the following:

Quan Chen, Fan Gao, Laurence J. Miller.
Cholecystokinin receptors: CCK2 receptor. Last modified on 19/09/2013. Accessed on 19/04/2014. IUPHAR database (IUPHAR-DB), http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=77.

Contact us | Print | Back to top | Help
Copyright © 2014 IUPHAR